Status: Recruiting
Kamuvudine-9 (K9) in Diabetic Macular Edema
The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo
Participants needed: 10
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Dr. Bryan StrelowUpdated: Mar 10, 2026Locations: 1
Eligibility criteria
Aged 18 years or older. [+11]
Body weight < 55 kg. [+27]